Larimar Therapeutics

What Larimar Therapeutics does

Larimar Therapeutics is a clinical-stage biotechnology company headquartered in Bala Cynwyd, Pennsylvania, founded in 2005 and listed on NASDAQ under ticker LRMR. The company is developing treatments for complex rare diseases, with its entire pipeline anchored on a single lead asset, nomlabofusp (formerly CTI-1601), a recombinant fusion protein designed to deliver functional frataxin protein to patients suffering from Friedreich's ataxia, a rare autosomal recessive neurodegenerative disorder with no approved disease-modifying therapy. The asset is built on a proprietary Cell Penetrating Peptide (CPP) technology platform that enables intracellular delivery of therapeutic proteins, and in February 2026 the FDA granted Breakthrough Therapy Designation based on clinical data showing increased skin frataxin levels and directional improvements across four key clinical outcomes after one year of treatment. Larimar has also secured FDA alignment on skin frataxin as a novel surrogate endpoint supporting an accelerated approval pathway.

Larimar is currently pre-commercial and generates no product revenue, reporting a Q1 2026 net loss of $29.6 million against a $200.4 million cash position that extends runway into Q2 2027. The company is preparing a U.S. commercial launch targeted for H1 2027 via a specialty-pharmacy distribution model aimed at rare-disease specialists and academic medical centers, contingent on FDA approval of a rolling Biologics License Application submission planned for June 2026. Capital has been raised through multiple public and private equity offerings since 2021, including a $95 million private placement in May 2021, a $70 million public offering in September 2022, a $172.5 million offering in February 2024, a $69 million offering in July 2025, and a $100 million upsized offering with a concurrent $25 million Deerfield investment in February 2026. Institutional ownership stands at 91.92%, with ten brokerages maintaining consensus Buy ratings and price targets ranging from $9 (JPMorgan) to $26 (Guggenheim) and a global Phase 3 confirmatory study planned across the U.S., EU, U.K., Canada, and Australia.

Name

Larimar Therapeutics

Legal name

Larimar Therapeutics, Inc.

Website

https://larimartx.com

Company type

Public

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Larimar Therapeutics is a clinical-stage biotechnology company developing nomlabofusp, a first-in-class frataxin replacement therapy for Friedreich's ataxia using its proprietary Cell Penetrating Peptide platform, with FDA Breakthrough Therapy Designation granted in February 2026 and planned U.S. launch in H1 2027.

Ownership category

akta.pro rank

Product category

Rare Disease Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro industry

PRIMARYHLAIAIAN

Rare Pediatric & Congenital Disorder Therapies

Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

SECONDARYHLAAAAAJ

Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)

Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

• Rare disease therapeutics
• Protein replacement therapy
• Biopharmaceutical drug development
• Friedreich's ataxia treatment
• Clinical-stage biotechnology

Headquarters

HQ city

Bala Cynwyd

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Larimar is a pre-commercial clinical-stage biotechnology company with no current revenue. It is preparing for commercial launch of nomlabofusp following FDA approval, anticipated in H1 2027. Revenue will be generated through prescription drug sales, likely distributed through specialty pharmacy channels.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Larimar Therapeutics is a clinical-stage biotechnology company developing nomlabofusp (formerly CTI-1601), a recombinant fusion protein designed as a frataxin replacement therapy for Friedreich's ataxia in adults and children. The product leverages the company's proprietary Cell Penetrating Peptide (CPP) technology platform to deliver functional frataxin protein into cells, and if approved would be the first frataxin replacement therapy for the disease. The company plans a rolling BLA submission in June 2026 with anticipated U.S. commercial launch in H1 2027.

Product overview

Larimar Therapeutics is a clinical-stage biotechnology company developing treatments for rare diseases. The company's lead product candidate is nomlabofusp, a frataxin protein replacement therapy for Friedreich's ataxia. The company utilizes a cell penetrating peptide (CPP) technology platform to develop its therapeutic candidates. Nomlabofusp is advancing toward a planned Biologics License Application (BLA) submission in June 2026 following FDA Breakthrough Therapy Designation, with potential U.S. approval and launch expected in the first half of 2027.

Differentiator

Problem solved

Functional benefit

Products and services

• Nomlabofusp (CTI-1601) Nomlabofusp is a recombinant fusion protein designed as a frataxin replacement therapy for Friedreich's ataxia in adults and children. It uses Larimar's proprietary Cell Penetrating Peptide (CPP) technology to deliver functional frataxin protein into cells, with clinical data showing increased skin frataxin levels and directional improvements across four key clinical outcomes after one year of treatment. If approved, it would be the first frataxin replacement therapy for Friedreich's ataxia.

Quantifiable outcome

• Increased skin frataxin levels observed after one year of treatment in ongoing open-label study
• +4 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators16 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Solid Biosciences: Gene therapy company with a Friedreich's ataxia program in its pipeline. Direct indication peer pursuing a curative one-time approach that competes with Larimar's chronic dosing strategy.
• Lexeo Therapeutics: Clinical-stage gene therapy company developing LX2006, an AAV-based frataxin gene therapy for Friedreich's ataxia cardiomyopathy. Direct competition in the same indication with a one-time dosing modality that could disrupt Larimar's chronic protein-replacement model.
• Design Therapeutics: Clinical-stage biotech developing a gene-targeted therapy (DT-216) for Friedreich's ataxia aimed at the underlying GAA repeat expansion. Direct indication peer with a differentiated mechanism but overlapping patient population.
• Voyager Therapeutics: Clinical-stage gene therapy company with a CNS/neurological rare-disease pipeline including Friedreich's ataxia programs. Comparable as a neurology-focused rare-disease biotech using novel delivery platforms.

Direct peers

• Reata Pharmaceuticals (a Biogen company): Reata developed and gained FDA approval of Skyclarys (omaveloxolone) for Friedreich's ataxia, the only approved disease-targeting therapy in FA. It is the most directly comparable peer in indication and patient population, though it acts via a different mechanism (Nrf2 activator) versus Larimar's protein replacement.

Regional players

• Minoryx Therapeutics: Spain-based clinical-stage company developing leriglitazone, a brain-penetrant PPAR-γ agonist, for Friedreich's ataxia (and X-ALD). Direct indication peer in FA targeting CNS/neurological manifestations; primary commercial focus is ex-U.S. (Europe).

Broad incumbents

• BioMarin Pharmaceutical: Established rare-disease biotech specializing in enzyme and protein replacement therapies (e.g., Naglazyme, Vimizim, Aldurazyme). Comparable business model: develops and commercializes biologics for ultra-rare genetic disorders globally.
• Ultragenyx Pharmaceutical: Commercial-stage rare-disease biotech with multiple approved biologic/replacement therapies (e.g., Crysvita, Dojolvi). Comparable as a protein-replacement-focused rare-disease company targeting genetic deficiencies with limited treatment options.
• Sarepta Therapeutics: Commercial-stage rare-disease company specializing in genetic medicines (gene therapy, RNA) for Duchenne muscular dystrophy and other rare neuromuscular disorders. Comparable as a high-stakes, single-platform rare-disease biotech navigating accelerated approvals and safety scrutiny.
• Alexion / AstraZeneca Rare Disease: Global rare-disease franchise within AstraZeneca with multiple approved biologic therapies (e.g., Soliris, Ultomiris, Strensiq) for ultra-rare disorders. Comparable as a rare-disease biologics commercializer with deep specialty distribution and global launch infrastructure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/larimarthrx

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds14 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Larimar Therapeutics